Hims & Hers Health (HIMS) is moving higher as investors lean into a near-term catalyst setup ahead of its next earnings report. The company is scheduled to release first-quarter 2026 results after the close on Monday, May 11, 2026, and the stock is seeing pre-earnings positioning tied to expectations for subscriber growth, marketing efficiency, and GLP-1-related revenue trends.

Sentiment has improved in recent weeks after the company expanded its platform to offer a broader range of FDA-approved GLP-1 medications, a shift that investors view as supportive of more durable growth and reduced legal/regulatory overhang versus reliance on compounded alternatives. The GLP-1 category remains a key swing factor for near-term revenue momentum and customer acquisition costs, making it a focal point into the May 11 report.

Hims & Hers recently announced an agreement to acquire Eucalyptus, with the transaction expected to close in the middle of calendar year 2026, subject to regulatory approvals and other customary conditions. Traders are increasingly treating the deal as a potential accelerant for international expansion and category breadth, while also watching for any signals about integration costs and near-term margin impacts.

HIMS has carried elevated short interest metrics in recent disclosures, which can intensify day-to-day price action when sentiment turns constructive. With earnings less than a week away, that setup can contribute to incremental buying pressure as some bearish positioning is reduced and options activity increases into the event.